

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/002970-2021>

Contract

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Business Energy and Industrial Strategy

F03: Contract award notice

Notice identifier: 2021/S 000-002970

Procurement identifier (OCID): ocids-h6vhtk-029301

Published 12 February 2021, 5:45pm

Section I: Contracting authority

I.1) Name and addresses

Business Energy and Industrial Strategy

1 Victoria Street

London

SW1H0ET

Email

VTFCContracts@beis.gov.uk

Country

United Kingdom

NUTS code

UK - UNITED KINGDOM

Internet address(es)

Main address

<https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

General public services

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Reference number

4846/01/2021

II.1.2) Main CPV code

- 33651600 - Vaccines

II.1.3) Type of contract

Supplies

II.1.4) Short description

Procurement of Janssen's vaccine candidate Ad26.COV2-S.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £1

II.2) Description

II.2.3) Place of performance

NUTS codes

- BE - BELGIUM

II.2.4) Description of the procurement

This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)).

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.14) Additional information

Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- Extreme urgency brought about by events unforeseeable for the contracting authority

Explanation:

The award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c)).

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract

Contract No

4846/01/2021

Title

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

15 January 2021

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

JANSSEN PHARMACEUTICA NV

30 Turnhoutseweg

Beerse

B-2340

Country

Belgium

NUTS code

- BE - BELGIUM

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £1

Total value of the contract/lot: £1

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

Department of Business, Energy and Industrial Strategy

1 Victoria Street

London

SW1H 0ET

Country

United Kingdom